Gastric point-of-care ultrasound in the GLP-1 receptor agonist era: clinical impact and competency.
No abstract available
References:
Kruisselbrink R, Gharapetian A, Chaparro LE, Ami N, Richler D, Chan VWS, Perlas A. Diagnostic accuracy of point‐of‐care gastric ultrasound. Anesth Analg 2019; 128: 89–95. https://doi.org/10.1213/ANE.0000000000003372.
Alakkad H, Kruisselbrink R, Chin KJ, Niazi AU, Abbas S, Chan VWS, Perlas A. Point‐of‐care ultrasound defines gastric content and changes the anesthetic management of elective surgical patients who have not followed fasting instructions: a prospective case series. Can J Anaesth 2015; 62: 1188–1195. https://doi.org/10.1007/s12630‐015‐0449‐1.
O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double‐blind, placebo and active controlled, dose‐ranging, phase 2 trial. Lancet 2018; 392: 637–649. https://doi.org/10.1016/S0140‐6736(18)31773‐2.
Marso SP, Daniels GH, Brown‐Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. Drug Ther Bull 2016; 54: 101. https://doi.org/10.1056/NEJMoa1603827.
Sen S, Potnuru PP, Hernandez N, Goehl C, Praestholm C, Sridhar S, Nwokolo OO. Glucagon‐like peptide‐1 receptor agonist use and residual gastric content before anesthesia. JAMA Surg 2024; 159: 660–667. https://doi.org/10.1001/jamasurg.2024.0111.